New/direct oral anticoagulants (DOAK)

Praxis (Bern 1994). 2023 Dec;112(13):616-627.ABSTRACTDue to their advantageous benefit-risk-profile, direct oral anticoagulants (DOACs) are preferred over vitamin-K-antagonists for stroke prevention in atrial fibrillation as well as therapy and secondary prevention of venous thromboembolism. This guideline provides information on the practical use of DOACs, their advantages and disadvantages and limitations. It is based on recommendations from international guidelines (ESC, EHRA, DGA) and adapts them for the general practitioner setting in Switzerland.PMID:38193470

Source: Praxis - January 9, 2024 Category: General Medicine Authors: Andrea Rosemann Oliver Senn Stefan Neuner-Jehle Stefan Markun Giuseppe Pichierri Thomas Rosemann Source Type: research